Pharma Equity Group AS (OCSE:PEG) EPS without NRI: kr-0.02 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharma Equity Group AS EPS without NRI?

Pharma Equity Group AS OCSE:PEG +4.88% EPS without NRI is kr-0.02 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 1,168 Biotechnology companies, Pharma Equity Group AS ranks worse than 89.04% on this metric.

Pharma Equity Group AS's earnings per share without non-recurring items for the six months ended in Dec. 2025 was kr-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Pharma Equity Group AS's EPS without NRI or its related term are showing as below:

OCSE:PEG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -367.2   Med: 37.4   Max: 85.4
Current: -26

OCSE:PEG's 3-Year EPS without NRI Growth Rate is ranked worse than
89.04% of 1168 companies
in the Biotechnology industry
Industry Median: 16.4 vs OCSE:PEG: -26.00

Pharma Equity Group AS's EPS (Diluted) for the six months ended in Dec. 2025 was kr-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.02.

Pharma Equity Group AS's EPS (Basic) for the six months ended in Dec. 2025 was kr-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.02.


Pharma Equity Group AS  (OCSE:PEG) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Pharma Equity Group AS EPS without NRI Related Terms


Pharma Equity Group AS EPS without NRI Historical Data

* Premium members only.

The historical data trend for Pharma Equity Group AS's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group AS EPS without NRI Chart

Pharma Equity Group AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.01 -0.02 -0.02 -0.02

Pharma Equity Group AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

OCSE:PEG vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Pharma Equity Group AS's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group AS PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's PE Ratio without NRI falls into.



Pharma Equity Group AS EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of kr-0.02 mean?
Pharma Equity Group AS (OCSE:PEG) has a EPS without NRI of kr-0.02 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Pharma Equity Group AS and its competitors. According to the industry distribution chart, Pharma Equity Group AS ranks #1040 out of 1168 companies in the Biotechnology industry, placing it in the top 89%.
Is Pharma Equity Group AS's EPS without NRI too high?
Pharma Equity Group AS's current EPS without NRI is kr-0.02. Based on the distribution chart, Pharma Equity Group AS ranks #1040 out of 1168 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Pharma Equity Group AS's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #1040 out of 1168 companies for EPS without NRI. This places Pharma Equity Group AS in the lower half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Pharma Equity Group AS and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Equity Group AS's current EPS without NRI is kr-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current EPS without NRI of kr-0.02. The current EPS without NRI is kr-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current EPS without NRI is kr-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharma Equity Group AS Business Description

Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .